<div><strong>Help mijn vader toegang te krijgen tot CAR-T-celtherapie</strong>
</div>
<div><br />
</div>
<div>Hallo allemaal,
</div>
<div><br />
</div>
<div>Mijn naam is Linda en ik zamel geld in voor mijn vader, die onlangs de diagnose non-Hodgkin lymfoom heeft gekregen, specifiek een folliculair lymfoom, een type B-cel lymfoom in stadium IV, wat betekent dat het zich in een vergevorderd stadium bevindt en als 'hoog risico' wordt beschouwd. Deze vorm van lymfeklierkanker wordt vaak gekenmerkt door een langzaam verloop, maar in dit stadium is moeilijk te behandelen.
</div>
<div><br />
</div>
<div>Momenteel wordt er een 'wait-and-see'-beleid gehanteerd, waarbij behandeling pas start wanneer de symptomen verergeren. Echter, er is een innovatieve behandeling beschikbaar: CAR-T-celtherapie. Deze therapie heeft veelbelovende resultaten laten zien bij patiënten met terugkerende of refractaire vormen van folliculair lymfoom. In een recente studie werd een objectieve responsratio van 95% waargenomen bij patiënten met folliculair lymfoom, waarvan velen een complete remissie bereikten.
</div>
<div><br />
</div>
<div>Helaas wordt deze behandeling niet vergoed omdat mijn vader niet voldoet aan de strikte criteria die de zorgverzekeraar stelt. De kosten zijn aanzienlijk, maar deze therapie biedt de kans op een langer en kwalitatief beter leven voor mijn vader.
</div>
<div><br />
</div>
<div>Mijn vader is een echte levensgenieter met een groot sociaal netwerk. Altijd positief, bereid anderen te helpen en gek op zijn kleinzoon. We willen niets liever dan dat hij nog vele jaren bij ons blijft. Het voelt oneerlijk dat financiële barrières zijn toegang tot deze potentiële levensreddende behandeling beperken.
</div>
<div><br />
</div>
<div><strong>Hoe kunt u helpen?</strong>
</div>
<div><em>Doneren:</em> Elke bijdrage, groot of klein, brengt ons dichter bij het doel om de behandeling mogelijk te maken.
</div>
<div><em>Delen:</em> Verspreid deze oproep binnen uw netwerk om ons bereik te vergroten.
</div>
<div><br />
</div>
<div>Liefs,
</div>
<div>Linda
</div>
<div><br />
</div>
<div><strong>Wetenschappelijke artikelen over CAR-T-celtherapie:</strong>
</div>
<div><br />
</div>
<div><a href="https://www.erasmusmc.nl/nl-nl/kankerinstituut/patientenzorg/behandelingen/car-t-celtherapie" target="_blank" rel="noreferrer noopener"><a href="https://www.erasmusmc.nl/nl-nl/kankerinstituut/patientenzorg/behandelingen/car-t-celtherapie" target="_blank" class="" rel="nofollow noopener noreferrer">https://www.erasmusmc.nl/nl-nl/kankerinstituut/patientenzorg/behandelingen/car-t-celtherapie</a></a>
</div>
<div><br />
</div>
<div><a href="https://www.hematon.nl/thema-s/behandelingen/car-t-celtherapie?utm_source=chatgpt.com" target="_blank" rel="noreferrer noopener"><a href="https://www.hematon.nl/thema-s/behandelingen/car-t-celtherapie?utm_source=chatgpt.com" target="_blank" class="" rel="nofollow noopener noreferrer">https://www.hematon.nl/thema-s/behandelingen/car-t-celtherapie?utm_source=chatgpt.com</a></a>
</div>
<div><br />
</div>
<div><a href="https://www.kanker.nl/kankersoorten/non-hodgkinlymfoom/behandelingen/car-t-cel-therapie-bij-non-hodgkin?utm_source=chatgpt.com" target="_blank" rel="noreferrer noopener"><a href="https://www.kanker.nl/kankersoorten/non-hodgkinlymfoom/behandelingen/car-t-cel-therapie-bij-non-hodgkin?utm_source=chatgpt.com" target="_blank" class="" rel="nofollow noopener noreferrer">https://www.kanker.nl/kankersoorten/non-hodgkinlymfoom/behandelingen/car-t-cel-therapie-bij-non-hodgkin?utm_source=chatgpt.com</a></a>
</div>
<div><br />
</div>
<div><a href="https://info.mumc.nl/pub-1811?utm_source=chatgpt.com" target="_blank" rel="noreferrer noopener"><a href="https://info.mumc.nl/pub-1811?utm_source=chatgpt.com" target="_blank" class="" rel="nofollow noopener noreferrer">https://info.mumc.nl/pub-1811?utm_source=chatgpt.com</a></a>
</div>
<div><br />
</div>
<div><a href="https://pubmed.ncbi.nlm.nih.gov/34248965/" target="_blank" rel="noreferrer noopener"><a href="https://pubmed.ncbi.nlm.nih.gov/34248965/" target="_blank" class="" rel="nofollow noopener noreferrer">https://pubmed.ncbi.nlm.nih.gov/34248965/</a></a>
</div>
<div><br />
</div>
<div><a href="https://www.cancer.gov/news-events/cancer-currents-blog/2022/nhl-car-t-cells-belinda-transform-zuma7" target="_blank" rel="noreferrer noopener"><a href="https://www.cancer.gov/news-events/cancer-currents-blog/2022/nhl-car-t-cells-belinda-transform-zuma7" target="_blank" class="" rel="nofollow noopener noreferrer">https://www.cancer.gov/news-events/cancer-currents-blog/2022/nhl-car-t-cells-belinda-transform-zuma7</a></a>
</div>
<div><br />
</div>
<div><a href="https://www.cityofhope.org/research/car-t-cell-therapy/nhl-car-t" target="_blank" rel="noreferrer noopener"><a href="https://www.cityofhope.org/research/car-t-cell-therapy/nhl-car-t" target="_blank" class="" rel="nofollow noopener noreferrer">https://www.cityofhope.org/research/car-t-cell-therapy/nhl-car-t</a></a>
</div>
<div><br />
</div>
<div><a href="https://stemcell.ucla.edu/news/new-car-t-approach-minimizes-resistance-helps-avoid-relapse-non-hodgkins-b-cell-lymphoma" target="_blank" rel="noreferrer noopener"><a href="https://stemcell.ucla.edu/news/new-car-t-approach-minimizes-resistance-helps-avoid-relapse-non-hodgkins-b-cell-lymphoma" target="_blank" class="" rel="nofollow noopener noreferrer">https://stemcell.ucla.edu/news/new-car-t-approach-minimizes-resistance-helps-avoid-relapse-non-hodgkins-b-cell-lymphoma</a></a>
</div>
<div><br />
</div>
<div><br />
</div>
<div><strong>Help My Father Access CAR-T Cell Therapy</strong>
</div>
<div><br />
</div>
<div>Hello everyone,
</div>
<div><br />
</div>
<div>My name is Linda, and I am raising funds for my father, who was recently diagnosed with non-Hodgkin lymphoma, specifically follicular lymphoma, a type of B-cell lymphoma at stage IV. This means his disease is in an advanced stage and classified as "high risk." This form of lymphoma is often characterized by a slow progression, but at this stage, it is difficult to treat.
</div>
<div><br />
</div>
<div>Currently, a "wait-and-see" approach is being followed, meaning treatment will only begin when symptoms worsen. However, an innovative treatment is available: CAR-T cell therapy. This therapy has shown promising results in patients with recurrent or refractory forms of follicular lymphoma. A recent study observed an objective response rate of 95%, with many patients achieving complete remission.
</div>
<div><br />
</div>
<div>Unfortunately, this treatment is not covered by the insurance provider because my father does not meet the strict eligibility criteria. The costs are significant, but this therapy offers him the chance for a longer and better quality life.
</div>
<div><br />
</div>
<div>My father is a true life enthusiast with a large social network. He is always positive, always willing to help others, and absolutely devoted to his grandson. More than anything, we want him to be with us for many more years. It feels unfair that financial barriers are preventing him from accessing this potentially life-saving treatment.
</div>
<div><br />
</div>
<div><strong>How Can You Help?</strong>
</div>
<div><em>Donate:</em> Every contribution, big or small, brings us closer to making this treatment possible.
</div>
<div><em>Share:</em> Spread this fundraiser within your network to help us reach more people.
</div>
<div><br />
</div>
<div>Thank you from the bottom of our hearts for your support.
</div>
<div><br />
</div>
<div>With love,
</div>
<div>Linda
</div>
<div><br />
</div>
<div><strong>Scientific Articles on CAR-T Cell Therapy:</strong>
</div>
<div><a href="https://www.erasmusmc.nl/nl-nl/kankerinstituut/patientenzorg/behandelingen/car-t-celtherapie" target="_blank" rel="noreferrer noopener"><a href="https://www.erasmusmc.nl/nl-nl/kankerinstituut/patientenzorg/behandelingen/car-t-celtherapie" target="_blank" class="" rel="nofollow noopener noreferrer">https://www.erasmusmc.nl/nl-nl/kankerinstituut/patientenzorg/behandelingen/car-t-celtherapie</a></a>
</div>
<div><br />
</div>
<div><a href="https://www.hematon.nl/thema-s/behandelingen/car-t-celtherapie" target="_blank" rel="noreferrer noopener"><a href="https://www.hematon.nl/thema-s/behandelingen/car-t-celtherapie?utm_source=chatgpt.com" target="_blank" class="" rel="nofollow noopener noreferrer">https://www.hematon.nl/thema-s/behandelingen/car-t-celtherapie?utm_source=chatgpt.com</a></a>
</div>
<div><br />
</div>
<div><a href="https://www.kanker.nl/kankersoorten/non-hodgkinlymfoom/behandelingen/car-t-cel-therapie-bij-non-hodgkin" target="_blank" rel="noreferrer noopener"><a href="https://www.kanker.nl/kankersoorten/non-hodgkinlymfoom/behandelingen/car-t-cel-therapie-bij-non-hodgkin?utm_source=chatgpt.com" target="_blank" class="" rel="nofollow noopener noreferrer">https://www.kanker.nl/kankersoorten/non-hodgkinlymfoom/behandelingen/car-t-cel-therapie-bij-non-hodgkin?utm_source=chatgpt.com</a></a>
</div>
<div><br />
</div>
<div><a href="https://info.mumc.nl/pub-1811" target="_blank" rel="noreferrer noopener"><a href="https://info.mumc.nl/pub-1811?utm_source=chatgpt.com" target="_blank" class="" rel="nofollow noopener noreferrer">https://info.mumc.nl/pub-1811?utm_source=chatgpt.com</a></a>
</div>
<div><br />
</div>
<div><a href="https://pubmed.ncbi.nlm.nih.gov/34248965" target="_blank" rel="noreferrer noopener"><a href="https://pubmed.ncbi.nlm.nih.gov/34248965/" target="_blank" class="" rel="nofollow noopener noreferrer">https://pubmed.ncbi.nlm.nih.gov/34248965/</a></a>
</div>
<div><br />
</div>
<div><a href="https://www.cancer.gov/news-events/cancer-currents-blog/2022/nhl-car-t-cells-belinda-transform-zuma7" target="_blank" rel="noreferrer noopener"><a href="https://www.cancer.gov/news-events/cancer-currents-blog/2022/nhl-car-t-cells-belinda-transform-zuma7" target="_blank" class="" rel="nofollow noopener noreferrer">https://www.cancer.gov/news-events/cancer-currents-blog/2022/nhl-car-t-cells-belinda-transform-zuma7</a></a>
</div>
<div><br />
</div>
<div><a href="https://www.cityofhope.org/research/car-t-cell-therapy/nhl-car-t" target="_blank" rel="noreferrer noopener"><a href="https://www.cityofhope.org/research/car-t-cell-therapy/nhl-car-t" target="_blank" class="" rel="nofollow noopener noreferrer">https://www.cityofhope.org/research/car-t-cell-therapy/nhl-car-t</a></a>
</div>
<div><br />
</div>
<div><a href="https://stemcell.ucla.edu/news/new-car-t-approach-minimizes-resistance-helps-avoid-relapse-non-hodgkins-b-cell-lymphoma" target="_blank" class="" rel="nofollow noopener noreferrer">https://stemcell.ucla.edu/news/new-car-t-approach-minimizes-resistance-helps-avoid-relapse-non-hodgkins-b-cell-lymphoma</a>
</div>
<div><br />
</div>

Roderik Zaalberg

Ymke Goedhart

Ed & Anita Groeneveld

Miranda Van Kessel

Anonymous

Agnes Feher

Ilan Harel

Mij niet bellen Van Ettinger

Marielle Verkley

G.C. Geenen

Sabine van leijden

Yvonne Tjoonk

Willem Mes

Amber De Bruin

Reggie Hoefman

Harry Houweling

Marco M

Cheyenne Slagmoolen

Antoinette Eilering

Help mijn vader langer van het leven te genieten!

platform

Platform is iOS

Android

Adyen Google Pay Development Audience

$opt_dummy_attribute

English only

Deprecate Stripe Legacy

dyn_template_ids

Adyen V6 Bene Transfer & MyMoney Campaign Organizers - test01

Bene transfer V6 and AdyenV6MyMoney Campaign Organizers - production

OneTrust next-app audience

fundCountryCode

NextDoor Share Option Users

Fundraisers with Reactions feature capability

fundCurrencyCode

US + Non-charity COs Only

locale

fund country is US and user language is English

personId

comms-internal-person-ids

Enhanced Story Experience Users

Suggested Goal Experience Users

user language is English and fund country: US, AU, DK, FI, IE, NO, SE, CA, GB; 

Poster share - new funds eligible (newest 9/18)

Streaming widgets beta user

paymentProcessor

3DS payment method

user language is English and fundCountry: US, AU, DK, FI, IE, NO, SE, CA, GB; 

currencyCode

Money Box Donation List Prompt Experiment Audience

GoFundMe Employees

ipAddress

Mark Rieth IP Address

Version 9.2.0 and above

Fund is in English speaking country

desktop

Android v12.11.0 and above

Platform is Android

paymentMethodType

checkoutType

Payment method type group to be vaulted on success

admin pr kit prod

EUR Donation Upsell

Share Text generation Skip Fundraiser

(prod) new funds eligible for amp12 (UGC gallery)

fintrac_cad_idv_form_v2 audience

paymentProcessorAccountId

fallback mode accounts

proCampaignId

p2p legacy startfundraising page

AMP24 New Funds Only PROD (DO NOT MODIFY)

Eligible for Profile Share Badge

countryCode

charityId

UKCharities

Federated Search Internal Testing

route.pathname community

US Donation Upsell audience 

Auto Thanks Feature Audience

Supporter Comments Eligible Funds

International Only

fundId

braze fundraiser group 

Payment Identity Transfers ATO Risk Check (Targeted) - Production

Fundraiser Saved Payment Method Rate Limit Bypass (Production)

leaderboard-partner-id-audience-givepanel

Version 9.2.1 and above

AUD Donation Upsell audience

fundraiserCountryCode is US/EN

Active Fundraiser - Smart Default Cadence

DAF Internal

Vault on success card payment method

Platform is iOS v11.0.0 and above

Desktop users

Person ids

United States (US) users

allow yuno fundraisers for test

Mexico country code

Posters INTL

NPO Profile Opted-In

iOS at or above 12.4.0

non-US recurring donors

Canada Campaign Owner Group

Fundraiser Without Meta Link

Scheduler payment tester gorup

charityCommunityId

Charities allow to be claimed unclaimed (PRD)

Canada (CA) users

UC Tipping v20250115 International

pymk_production_xplr_fe_team

Android at or above 12.2.0

Profile photo entry point audience

smart goals (fundraiser/manage) on test01

Activity Tracking v1 Beta Testing

start gfm intl allowed locales

Platform is iOS v11.2.0 and above

NPO upsell education category

unclaimed charities

prod_ach_audience

AI Chatbot Audience

amp13 only new funds (prod) (anyword auto)

UC Flow Enabled (Prod)

Payment Identity Beneficiary Verification - Production

shared notification bell audience

Custom users

ach frontend audience

Android v11.0.0 and above

Users Receiving Payments Paused Notifications

smart goals test01

Manage Coach - US English Organizers Only + new funds only

Team EGG - IP Address list

NPO recommendations prod

Fundraiser Without Instagram Deep Link

Native 11.4.0 and above

UC Tipping v20250107

Users Receiving Braze KYC Validation Failed

ai_title_page

anyword

openai

control

manual_entry

userEmail

template_id

userId

fundUrl

isCharityCo

email

appVersion

shouldBucketIntoExperiment

isEligibleForProfileBadge

partnerId

donationCadence

isActiveFundraiser

isPartner

isMobile

npoProfileOptIn

fundIsLinkedWithMeta

hasSessionDonation

categoryGroup

isCampaignOwner

fundHasInstagramDeepLink

Native 11.3.0 and above

Native 11.4.0 and higher

New funds eligible - Video Sharing (PROD)

GB Donation Upsell audience 

Auto Thanks V3 Rollout Audience

Thank you V3 testing whitelist

isRecurringFriendly

Is Recurring Friendly

Excluded funds - Video Sharing

NPO upsell animals category

NPO upsell disaster relief category

Logged In Users

CH Donation Upsell audience

Android v10.6.0 and above

NPO upsell essential needs category

NPO upsell medical category

userCurrencyCode

Localized Currency

NPO upsell cancer category

v11.5.0 and above

testAudience

pathname

Survicate

appVersion is at or above 12.8.0

Non-charity fund

isChallengeFundraiser

challenge-fundraisers

Payment Identity Launch Verification - Production

New funds eligible - Posters v2

CAD Donation Upsell Audience

Braze Email Tester

NPO Profile Opted-Out

iOS App Version

hasKnownDonors

PYMK has donors

iOS v12.3.0 and above

Help mijn vader langer van het leven te genieten!

Still €38,270 to go. Help us build momentum.